NewAmsterdam Pharma (NAMS) Common Equity (2021 - 2026)
NewAmsterdam Pharma's Common Equity was $631.42 million in Q2 2026, down 18.9% from $778.5 million a year earlier and down 5.1% from the prior quarter.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Common Equity (2021 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at NewAmsterdam Pharma came in at $683.43 million, down 9.8% from FY2024.
- In earlier years, Common Equity was $757.5 million in FY2024 (+162.7%), $288.39 million in FY2023 (-32.9%), $430.07 million in FY2022 and -$113.82 million in FY2021.
- The Q2 2026 figure marks the lowest quarterly Common Equity since Q3 2024.
- Compared with a year earlier, Common Equity has declined for three straight quarters, with growth averaging 52.0% over the last eight quarters.
- The best year-over-year quarter for Common Equity over five years was Q4 2022 (growth of 816.0%); the worst was Q4 2023 (a decline of 44.2%).
- Per Business Quant data, NAMS's Common Equity in the three quarters before Q2 2026 was $665.22 million (Q1 2026), $683.43 million (Q4 2025) and $728.07 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 40.27 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | -4.58 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 44.95 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 14.35 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 13.04 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 89.30 Bn |
| 10 | NewAmsterdam Pharma | 2.43 Bn | -108.81 Mn | - | 630.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 630.78 Mn |
| Jun 30, 2026 | 631.42 Mn |
| Mar 31, 2026 | 665.22 Mn |
| Dec 31, 2025 | 683.43 Mn |
| Sep 30, 2025 | 728.07 Mn |
| Jun 30, 2025 | 778.50 Mn |
| Mar 31, 2025 | 777.36 Mn |
| Dec 31, 2024 | 757.50 Mn |
| Sep 30, 2024 | 378.86 Mn |
| Jun 30, 2024 | 387.44 Mn |
| Mar 31, 2024 | 411.80 Mn |
| Dec 31, 2023 | 288.39 Mn |
| Sep 30, 2023 | 331.84 Mn |
| Jun 30, 2023 | 373.34 Mn |
| Mar 31, 2023 | 398.41 Mn |
| Dec 31, 2022 | 516.54 Mn |
| Dec 31, 2021 | 56.39 Mn |
API Access
NewAmsterdam Pharma Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=NAMS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "NAMS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=NAMS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();